The PEGylated liposomal (PEG-LP) Doxorubicin, PEG-LP (DOX), with a diameter 23 of around 100 nm, accumulates in tumors via the enhanced permeability and 24 retention (EPR) effect, and is used clinically for the treatment of several types of 25 cancer. However, there are a number of tumor types that are resistant to DOX. We 26 report herein on a unique anti-tumor effect of PEG-LP (DOX) in a DOX-resistant 27 tumor xenograft model. PEG-LP (DOX) failed to suppress the growth of the DOX-28 resistant tumors (ex. non-small cell lung cancer, H69AR; renal cell carcinoma, 29 OSRC-2) as observed in the xenograft model. Unexpectedly, tumor growth was 30 suppressed in a DOX-resistant breast cancer (MDA-MB-231) xenograft model. We 31 investigated the mechanism by which PEG-LP (DOX) responses differ in different 32 drug resistant tumors. In hyperpermeable OSRC-2 tumors, PEG-LP was distributed 33 to deep tumor tissues, where it delivers DOX to drug-resistant tumor cells. In 34 contrast, extracellular matrix (ECM) molecules such as collagen, pericytes, cancer-35 associated fibroblasts make the MDA-MB-231 tumors hypopermeable, which limits 36 the penetration and distribution of PEG-LP, and thereby enhances the delivery of 37 DOX around the tumor vasculature. Therefore, a remarkable anti-angiogenic effect 38 with a preferential suppression in tumor growth is achieved. Based on the above 39 findings, it appears that the response of PEG-LP (DOX) to drug-resistant tumors 40 results from differences in the tumor microenvironment. 41 42 43 44 Keywords 45 PEGylated liposome, Doxil, Drug-resistant cancer, Passive anti-angiogenesis, Anti-46 tumor effect 47 3
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to deep tumor tissues, where it delivers DOX to drug-resistant tumor cells. In 34 contrast, extracellular matrix (ECM) molecules such as collagen, pericytes, cancer-35 associated fibroblasts make the MDA-MB-231 tumors hypopermeable, which limits 36 the penetration and distribution of PEG-LP, and thereby enhances the delivery of 37 DOX around the tumor vasculature. Therefore, a remarkable anti-angiogenic effect 38 with a preferential suppression in tumor growth is achieved. Based on the above 39
findings, it appears that the response of PEG-LP (DOX) to drug-resistant tumors 40 results from differences in the tumor microenvironment. 41 3
Introduction 48
Chemotherapy, using several cytotoxic drugs including doxorubicin (DOX), is one of 49 major therapeutic approaches to the clinical treatment of cancers. However, the 50 major obstacle to the effective treatment of cancer is associated with the fact that 51 cancer cells eventually become resistant to chemotherapy, a phenomenon that is 52 commonly called cancer multidrug resistance (MDR) (Desoize and Jardillier, 2000; 53 Goldie, 2001; Niero et al., 2014) . Despite the strong cytotoxic effect, the unequal 54 biodistribution and severe adverse effects on normal healthy tissues (Swain et al., 55 2003) as well as the resistance of cancer cells limits the application of 56 chemotherapeutic drugs in clinics. Nanoparticles loaded with such drugs have the 57 ability to bypass the factors responsible for the MDR of cancer cells to the free drug 58 molecules, thereby are able to function more effectively against the MDR cancers 59 In cancer therapy, liposomes (LPs) have become an emerging and effective tool that 64 modifies the pharmacokinetics and distribution of drug molecules, thereby reducing 65 the toxicities associated with the use of chemotherapeutic drugs (Slingerland et In the present study, we present information regarding the unique anti-tumor effect 99
of PEG-LP (DOX) in DOX-resistant tumors. We investigated the therapeutic effect 100 of PEG-LP (DOX) in three different types of tumor models that are resistant to DOX, 101 and explored the mechanism by which PEG-LP (DOX) responds in a different 102 manner in different DOX-resistant tumors. conditions. 123 124
Preparation of DOX loaded PEG-LPs 125
The lipid film hydration method was also followed to prepare the LPs composed of 126 HSPC:Cholesterol (70:30) as described previously . Briefly, the 127 lipid film was hydrated with 155 mM ammonium sulfate for 25 min followed by a 128 probe sonication. DOX in PBS was added to the LPs (drug-to-lipid molar ratio of 129 1:10) followed by incubation at 60°C for 1 h, and the free DOX was removed by 130 means of an Amicon 50,000 MWCO filter. The amount of DOX in LPs was 131 determined by disintegration of the liposomal bilayer in methanol and colorimetric 132 determination of DOX concentration. The DOX loaded LPs were incubated with 5 mol% 133 6
Preparation of PEG-LPs for biodistribution study 135
The lipid film hydration method was used to prepare the PEGylated liposomes 136
(PEG-LPs). A lipid film composed of EPC/Cholesterol/PEG2000-DSPE/rhodamine-137 DOPE (molar ratio: 70/30/5/1) was formed by evaporation of the organic solvents 138 from the lipid solution in a glass tube. The lipid film was hydrated with the HEPES 139 buffer (10 mM, pH 7.4) followed by sonication for about 30 sec in a bath-type 140 sonicator (AU-25C, Aiwa, Tokyo, Japan). 141 142
Characterization of PEG-LPs 143
The prepared PEG-LPs were characterized by measuring its mean size and zeta 144 potential using a Zetasizer Nano ZS ZEN3600 instrument (Malvern Instruments 145
Ltd., Worchestershire, UK). The effect of free DOX on the viability of cells was determined by the WST-8 assay 161
protocol, as described previously . Briefly, 4,000 cells were 162 plated in 96-well plate and incubated overnight. The next day, the cells were 163 incubated with different doses of DOX for 8 h at 37°C, followed by reincubation for incubated with a cell counting kit-8 (CCK-8) solution (Dojindo) for 2 h and the 166 absorbance of the developed color was measured at 450 nm using a microplate 167 reader (Thermo Fisher Scientific Inc.). The same protocol was followed to compare 168 the cytotoxic effect of free DOX and DOX loaded PEG-LPs on the viability of MDA-169
MB-231 cells. In this case, the cells were incubated with different concentrations of 170 DOX (as free drug or encapsulated within the PEG-LPs) at 37°C for 8 h, followed by 171 reincubation for 16 h in the presence of fresh media. h, the previous medium was removed followed by washing with PBS and fresh 187 medium was added and the samples were reincubated for an additional 20 h, 188 followed by washing with PBS and fresh medium was added, followed by 189 injection (Fig. 1C-D) . On the other hand, PEG-LP (DOX) failed to suppress tumor 253 growth in the H69AR xenograft model (Fig. 1E-F) . The inefficiency of PEG-LP 254 (DOX) in inhibiting tumor growth was also observed in mice bearing the OSRC-2 255 tumors, as previously reported . These results indicate that DOX 256 loaded PEG-LP ((PEG-LP (DOX)) has a different therapeutic effect than free DOX 257 in different tumor types despite the fact that they are resistant to DOX. 258 259
Response of tumor cells to DOX 260
We further assessed the sensitivity of MDA-MB-231 to DOX by incubating the cells 261 with free DOX, and compared its effect with that of Hela cells as a sensitive tumor 262 cell model. As shown in Fig. 2 , the MDA-MB-231 cells showed a higher IC 50 value 263 To observe the effect of DOX on the morphology of cells, we incubated the MDA-MB-281 231 cells with free DOX or with DOX loaded PEG-LP, as shown in Fig. 3B . A huge 282 amount of DOX was detected inside the cells that had been treated with a higher 283 dose of drug, and the morphology of cells had changed, becoming round (Fig. 3B) , 
Intracellular distribution of PEG-LPs (DOX) 290
To observe and compare the distribution of DOX in various cellular compartments 291 in response to time, MDA-MB-231 cells were incubated with either free DOX or 292
PEG-LP (DOX). A huge amount of free DOX that had accumulated into cells within 293
a 3 h incubation period was detected in the nuclei of cells even after a 55 h culture 294 period (Fig. 4 ). Compared to free DOX, the amount of DOX delivered at the 3 h time 295 point by PEG-LP (DOX) was substantially lower, and the signals corresponding to 296 DOX in the nuclei were reduced gradually with passing time. 297 298
Evaluation of gene expression 300
Based on the results presented in Fig. 3 and Fig. 4 , it appears that the in vitro effect
301
of PEG-LP (DOX) on MDA-MB-231 cancer cells itself cannot be used to explain the 302 in vivo anti-tumor effect of PEG-LP (DOX) in mice bearing the MDA-MB-231 303 xenografts (Fig. 1C-D) . Therefore to explore the difference in the in vivo tumor OSRC-2 tumors, indicating that the MDA-MB-231 tumor is less angiogenic than the 310 OSRC-2 tumor. Additionally, as compared to OSRC-2 tumors, the expressions of 311 pericytes (NG2, normalized by CD31) and Pdgfrb markers were found to be 2-3 fold 312
higher in MDA-MB-231 tumors (Fig. 5A-B) , indicating that the MDA-MB-231 313 tumors are hypopermeable. These results suggest that MDA-MB-231 tumors are 314 less angiogenic and more hypopermeable than the OSRC-2 tumors. Furthermore, 315 the mRNA expression levels of several other genes including Col1a1 (ECM) and 316 Fapα (fibroblast markers) in MDA-MB-231 tumors were also found to be 317 approximately 2-3 fold higher than those in the OSRC-2 tumors (Fig. 5A) , 318
suggesting that the MDA-MB-231 tumors have a stroma rich environment as 319 To examine our hypothesis, we further observed the distribution of PEG-LP labeled 331 with fluorescence in the tumor tissues. Compared to the control, a huge amount of 332 PEG-LP was detected in the tumor, and where PEG-LP was found around the blood 333 vessels in the MDA-MB-231 tumor after i.v. injection (Fig. 6A) . It is well known that 334
PEG-LP passively accumulates in tumors via the EPR effect after intravenous 335
administration (Fang et al., 2011; Kibria et al., 2013; Maeda, 2012) . Based on the 336 images presented in Fig. 6A , it is likely that PEG-LP was directed to and 337 accumulated in the tumor tissues via the EPR effect, however, a large population of 338 the PEG-LP was present around the tumor blood vessels and it is possible that a 339 few might reach the tumor cells, given their concentrations. On the other hand, in 340 OSRC-2 tumors, most of the PEG-LPs that accumulated in the tumor were 341 extravasated and directed into deep tumor cells ( Fig. 6B and Fig. S1 ), as we 342 observed in a previous study . Taking these results into 343
consideration, it appears that PEG-LP (DOX) is unable to access the tumor cells in 344
MDA-MB-231 tumor tissues, but accumulates in the pre-vasculature region where 345 it might kill tumor endothelial cells and induce the anti-angiogenic effect. 346
347
To further explore the effect of PEG-LP (DOX) in more depth, we evaluated the 348 apoptosis of cells in the tumor microenvironment after the administration of PEG-349 LP (DOX) (Fig. 7) . Almost no signals corresponding to apoptotic cells were detected 350 in the MDA-MB-231 tumor treated with the free DOX. In contrast, a huge number 351 of cells undergoing apoptosis were detected in the tumor that had been treated with 352 PEG-LP (DOX), and most of the detected apoptosis signals were merged along with 353 the area of the tumor blood vessels. In addition, compared to the control or the free 354 DOX, signals for the tumor blood vessels were dramatically reduced in number in 355 the case of the tumor treated with PEG-LP (DOX) (Fig. 7A) , which is also evident in 356 the quantitative analysis showing a significant level of reduction in the area of the 357 blood vessels (Fig. 7B) . These results suggest that the anti-tumor effect of PEG-LP (Fig. 1A) , where the free DOX failed 386
to provide any detectable therapeutic effect. On the other hand, no anti-tumor effect 387 of PEG-LP (DOX) was observed in mice bearing H69AR tumors (Fig. 1C) , and 388 similarly, PEG-LP (DOX) was also observed to be inefficient in mice bearing OSRC- of PEG-LP (DOX) with that of the free DOX in MDA-MB-231 cells (Fig. 3A) . It was 394 observed that the free DOX exhibited a better cytotoxic effect and a change in the 395 morphology of the cells as compared to that of PEG-LP (DOX) in an in vitro 396 situation (Fig. 3) . Consequently, we explored the intracellular distribution of PEG-397 LP (DOX) as a function of time, as indicated in Fig. 4 . After a 3 h incubation, a huge 398 amount of free DOX was detected in MDA-MB-231 cells as compared to that of DOX 399 delivered by PEG-LP (DOX). With passing time, the DOX signal in cells that had 400 been treated with free DOX was clearly observed in the nuclei of cells where the 401 DOX actually functions (Fig. 4) , due to which free DOX exhibited a better cytotoxic 402 effect and change in cell morphology as compared to PEG-LP (DOX) in an in vitro 403 situation ( Fig. 3) . Moreover, the confocal microscope images suggested that the 404 uptake amount of DOX by PEG-LP (DOX) was lower than that of free DOX (Fig. 4) . 405
While free DOX can be readily taken up by the cells, the accumulation of DOX 406 depends on the amount of PEGylated liposomes that is taken up in the case of PEG-407 LP (DOX) (Fig. 4) . Therefore, the lower uptake of DOX delivered by PEG-LP (DOX) 408 could account for the inferior cytotoxicity of PEG-LP (DOX) compared to that of free 409 DOX (Fig. 3) . These results indicate that the in vivo therapeutic effect of PEG-LP
410
(DOX) (Fig. 1) in MDA-MB-231 breast tumors cannot be explained by its effect 411 observed in the in vitro studies (Fig. 3 and Fig. 4 ).
413
Therefore, we hypothesized that the difference in anti-tumor effects of PEG-LP 414 (DOX) between the MDA-MB-231 tumor and PEG-LP (DOX)-ineffective tumors (ex.
415
H29AR and OSRC-2), might result from differences in the tumor microenvironment. 416
To explore this further, we evaluated the expression of different genes associated 417 with the extracellular matrix (ECM) molecules (Fig. 5A ) in the tumors. Compared to 418
OSRC-2 tumors, the expression of pericytes or other ECM molecules in MDA-MB-419 231 tumors was found to be significantly higher ( Fig. 5A-B) . These results 420 demonstrate that the MDA-MB-231 tumors are stroma rich and their vasculatures are hypopermeable. To explore the effect of the ECM proteins on the penetration of 422 PEG-LP into DOX-resistant tumor tissues, we further evaluated the distribution of 423 PEG-LP (~100 nm) in the tumor microenvironment. Interestingly, based on the 424 results of the biodistribution study (Fig. 6A) , most of the PEG-LP was extravasated 425 via the EPR effect, accumulates and resides in close proximity to the blood vessels 426
of the MDA-MB-231 tumor. Therefore, the limited penetration and accumulation of 427 PEG-LP in the MDA-MB-231 tumor further demonstrates its hypopermeable 428 characteristics. Such an observation was also supported by the fact that most of the 429 DOX injected and delivered by the PEG-LP was found in the vicinity of tumor blood 430 vessels ( Fig. 7A ). Due to such an effect, DOX loaded PEG-LP ((PEG-LP (DOX)) 431
induced apoptosis (Fig. 7A ) of the cells present around the tumor blood vessels 432 including tumor endothelial cells (TECs) (Fig. 7A) , resulting in the disruption of the 433 tumor blood vessels, and finally inducing a significant anti-angiogenic effect ( Fig.  434 7B and Fig. 8 ). It is well established that angiogenesis of tumor blood vessels plays 435 a pivotal role in the growth and progression of tumors (Folkman, 1971 (Folkman, , 2007 . 436
Moreover, in tumor tissues, the growth and survival of tumor cells depends on life 437 support (blood, oxygen, nutrients, growth factors etc.) supplied by the TECs present 438 in the tumor blood vessels. In the case of tumor tissue, the percentage of ECs is very 439 low (~2%), and the number of tumor cells is about 100-times higher as compared to 440
ECs (Folkman, 1995; Matsuda et al., 2010) . It can be predicted that the killing of 441 one TEC by the drug molecule would lead to the suppression of growth or even the 442 death of many surrounding tumor cells (Hida et al., 2008; Molema et al., 1998) . 443
Therefore, it is reasonable to conclude that the anti-tumor effect of PEG-LP (DOX) 444 in the DOX-resistant MDA-MB-231 tumor (Fig. 1C-D) is mediated by the anti-445
angiogenic effect of PEG-LP (DOX) (Fig. 8) . 446
447
On the other hand, compared to MDA-MB-231 tumors, a significantly higher 448 expression of the CD31 gene was found in the OSRC-2 (RCC) tumors (Fig. 5A) , supported by the presence of comparatively lower levels of extracellular matrix 454 proteins (Fig. 5) . Hence, the leakiness of OSRC-2 tumor vasculatures dictates the 455 accumulation of PEG-LP (DOX) in deep tumor tissues where the tumor cells are 456 resistant to DOX (Fig. 8) . Therefore, in OSRC-2 tumors, apoptotic cells were nearly 457 absent in the tumor treated with the PEG-LP (DOX) (Fig. S2) . Moreover, no anti-458 angiogenic effect of PEG-LP (DOX) was observed in OSRC-2 tumors, indicating that 459 PEG-LP (DOX) fails to induce blood vessel disruption (Fig. S3) , and, as a result, has 460 negligible therapeutic effect (Kibria et al., 2013) ( Fig. 8) . Similar to the OSRC-2 461 tumor, the H69AR tumor would be predicted to show a similar distribution and 462 accumulation pattern of PEG-LP, which might lead to the failure of PEG-LP (DOX) 463 against the DOX-resistant H69AR tumor cells ( Fig. 1E-F) . intrinsic barriers likely play a pivotal role in the passive accumulation of PEG-LP 479 (DOX) around the vasculatures of MDA-MB-231 tumor tissues ( Fig. 6A and Fig. 7) , 480 and the subsequent delivery of DOX disrupts the tumor vasculature, eventually resulting in an anti-angiogenic effect. Such a process would induce a significant 482 anti-tumor effect for PEG-LP (DOX) in DOX resistant MDA-MB-231 tumors. 483
However, in an in vitro study, due to the higher cellular uptake of free DOX, the effect. Our study demonstrated that the ECM molecules preferentially limit the 504 penetration and accumulation of nanoparticles around the tumor vasculature and 505 such an effect contributes to the therapeutic efficacy of drug loaded nanoparticles in 506 MDR tumors. To overcome the limitations associated with the MDR in cancer, the 507 site of action of the drug delivered by the nanoparticles in the microenvironment of 508 the MDR tumors is critical and clearly needs to be elucidated for the development of 509 an effective drug delivery system for the treatment of MDR cancers in the future. 510 
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